866-997-4948(US-Canada Toll Free)

Coronary Stents Market in India 2013

Published By :

Netscribes (India) Pvt. Ltd.

Published Date : Oct 2013

Category :

Healthcare

No. of Pages : 134 Pages


Netscribes’ latest market research report titled Coronary stents Market in India 2013 states that manufacturers of coronary stents are experiencing high demand for their products due to a number of factors. Since cardiovascular diseases have become a common occurrence among the Indian population and the healthcare infrastructure in the country is rapidly improving, it has built a strong case for angioplasty procedures in the country. Moreover, an increase in awareness and the willingness to spend on healthcare is benefiting the market. Also, advancements in technology such as the introduction of bioabsorbable stents in the Indian market in December 2012 has made such stents more acceptable to patients, thereby providing further stimulus for market growth. With growth in the number of cath labs in the country and their subsequent expansion to smaller cities and towns, angioplasties will become more accessible to patients and will aid in further development of the market.

Products available in the market can be divided into two types – those manufactured by MNCs that command high prices, and those manufactured by domestic companies that are generally priced lower.  It is the MNCs that serve the majority of the market with almost all the big hospitals in tier I cities, where most of the angioplasties are performed, preferring to implant stents manufactured by foreign companies over those manufactured by their Indian counterparts. The general perception is that stents manufactured by MNCs are superior in terms of quality and efficacy, whereas those manufactured by domestic companies fail to attain similar high standards of quality. Also, patients are generally unaware of the choices they have in terms of the types of stents and the various brands that are available in the market, and have to buy stents directly from the hospitals. Since profit margins are higher in case of foreign-manufactured stents, hospitals push for the sale of such stents rather than selling the Indian varieties.

Since the medical equipment and devices industry in India has not been given any separate legal status and coronary stents have been classified as drugs under the provisions of the Drugs & Cosmetics Act, 1940, the Central Drugs Standard Control Organization (CDSCO) is responsible for the regulation of stents in the country. The reduction in reimbursement rates for stents under the Central Government Health Scheme (CGHS) in Feb 2013 has come as a body blow to manufacturers, especially the MNCs. Although majority of the angioplasties performed in the country are done in private establishments with only a few being done under the CGHS, the reduction in the reimbursement rates is likely to force companies to lower prices in the open market as well. The Drugs and Cosmetics (Amendment) Bill, 2013 was presented before the Parliament of India in August 2013 and if the Bill is passed, it will provide the growing medical devices sector an impetus in the form of a much needed regulatory mechanism and will benefit the coronary stents market as well.
Table of Content

Slide 1: Executive Summary

Macroeconomic Indicators
Slide 2: GDP at Factor Cost: Quarterly (2009-10, 2010-11, 2011-12, 2012-13), Inflation Rate: Monthly (Nov 2012 – Apr 2013)
Slide 3: Gross Fiscal Deficit: Monthly (Sep 2011-Feb 2012), Exchange Rate: Monthly (Dec 2012 – May 2013)
Slide 4: Lending Rate: Annual (2009-10, 2010-11, 2011-12, 2012-13), Trade Balance: Annual, FDI: Annual (2009-10, 2010-11, 2011-12, 2012-13)

Introduction
Slide 5: Coronary stents – Uses, Characteristics and Types
Slide 6: Development of Coronary Stents

Market Overview
Slide 7: Angioplasties – Overview and Number of Procedures Performed in India (2009 – 2017e)
Slide 8: Coronary Stents – Market Overview, Market Size & Growth (Value-Wise; 2011 – 2017e & Volume-Wise; 2011 – 2017e)
Slide 9: Drug-Eluting Stents – Market Overview, Market Size & Growth (Value-Wise; 2011 – 2017e & Volume-Wise; 2011 – 2017e)
Slide 10: Bare Metal Stents – Market Overview, Market Size & Growth (Value-Wise; 2011 – 2017e & Volume-Wise; 2011 – 2017e)
Slide 11: Bioabsorbable Stents – Market Overview, Market Size & Growth (Value-Wise; 2013e – 2017e & Volume-Wise; 2013e – 2017e)
Slide 12: Coronary Stents – Price Trends

Drivers & Challenges
Slide 13: Drivers and Challenges – Summary
Slide 14-18: Drivers
Slide 19-20: Challenges

Government Involvement
Slide 21: Organizational Structure of Regulatory Bodies
Slide 22-23: Regulatory Bodies
Slide 24-27: Regulatory Policies
Slide 28: Process of Obtaining License for Manufacturing Medical Device Regulated as Drugs in India
Slide 29-31: Requirements for Grant of License for Manufacture of Medical Devices in India
Slide 32: Process of Obtaining Registration for Import of Medical Device Regulated as Drugs in India
Slide 33-37: Documents Required for the Registering Medical Devices for Import into India

Competitive Landscape
Slide 38-40: Entry Barriers
Slide 41: Porter’s Five Forces Analysis
Slide 42: Competition Overview, Market Share of Companies (Volume-Wise; 2012)
Slide 43: Sale of Coronary Stents by Various Companies (2012)
Slide 44-47: Competitive Benchmarking 
Slide 48-96: Major Companies

Buyer Details
Slide 97: List of Top 10 Hospitals Buying Coronary Stents in India
Slide 98-127: Major Buyers
Slide 128: Other Major Purchasers of Stents

Recent Developments
Slide 129: Major Recent Developments in the Market

Strategic Recommendation
Slide 130-131: Key Recommendations
Slide 132: Opportunities by Geography

Appendix
Slide 133: Appendix
Slide 134: Sources of Information

List of Table


Market Overview
1. Coronary Stents – Price Trends

Government Involvement
1. Reimbursement Rates Under Central Government Health Scheme (2007, 2011, 2013)

Competitive Landscape
1. Company Profiles (All Companies)
a. Company Information (All Companies)
b. Products and Services (All Companies)
c. Key People (All Companies)
d. Shareholders of the Company (Private Companies, Except B. Braun Medical (India) Pvt. Ltd. & MIV Therapeutics (India) Pvt. Ltd.)
a. Key Financial Performance Indicators (Public Companies)
b. Key Ratios (Except Boston Scientific India Pvt. Ltd.)
e. Business Highlights (All Companies)

Buyer Details
1. Top 10 Hospitals Buying Coronary Stents In India
2. Buyer Profiles (All Companies)
c. Company Information (All Companies)
d. Products and Services (All Companies)
e. Key People (All Companies)
f. Business Highlights (All Companies)
g. Key Hospital Indicators
f. Stent Procurement Procedure

Appendix
2. Appendix
3. Sources of Information

List of Chart


Macro Economic Indicators
1. GDP at Factor Cost: Quarterly (2009-10, 2010-11, 2011-12, 2012-13)
2. Inflation Rate: Monthly (Nov-Dec 2012 – Mar-Apr 2013)
3. Gross Fiscal Deficit: Monthly (Sep 2011 - Feb 2012)
4. Exchange Rate: Monthly (Dec 2012 – May 2013)
5. Lending Rate: Annual (2009-10, 2010-11, 2011-12, 2012-13)
6. Trade Balance: Annual (2009-10, 2010-11, 2011-12, 2012-13)
7. FDI Annual (2009-10, 2010-11, 2011-12, 2012-13)

Market Overview
1. Number of Angioplasty Procedures (2009 – 2017e)
2. Coronary Stents – Market Size & Growth (Value-Wise; 2011 – 2017e)
3. Coronary Stents – Market Size & Growth (Volume-Wise; 2011 – 2017e)
4. Drug-Eluting Stents – Market Size & Growth (Value-Wise; 2011 – 2017e)
5. Drug-Eluting Stents – Market Size & Growth (Volume-Wise; 2011 – 2017e)
6. Bare Metal Stents – Market Size & Growth (Value-Wise; 2011 – 2017e)
7. Bare Metal Stents – Market Size & Growth (Volume-Wise; 2011 – 2017e)
8. Bioabsorbable Stents – Market Size & Growth (Value-Wise; 2013e – 2017e)
9. Bioabsorbable Stents – Market Size & Growth (Volume-Wise; 2013e – 2017e)

Drivers & Challenges
1. CVD Prevalence – Number of Patients (2011 – 2017e)
2. Diabetes Prevalence – Number of Patients (2011 – 2017e)
3. Budget Allocation of Funds for Healthcare Sector (2010-11 – 2013-14)
4. Private Hospitals Market in India (Value-Wise; 2011 – 2017e)
5. Population Above 60 Years (2011 – 2017e)
6. Average Life Expectancy (1960, 1970, 1980, 1990, 2000, 2011)
7. Household Expenditure – Share of Wallet % (2005, 2015e, 2025e)

Competitive Landscape
1. Market Share (Volume-Wise; 2012)
2. Competitive Benchmarking – Key Ratios of 4 Major Companies – Operational & Financial Basis (2011-2012)
3. Company profiles (All Companies)
a. Ownership Structure (Private Companies)
b. Financial Snapshot (Except Boston Scientific India Pvt. Ltd.) 
c. Key Business segments (Public Companies)
d. Key Geographic segments (Public Companies)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Dyslipidemia Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    Dyslipidemia is a lipoprotein metabolism disorder characterized by abnormal amount of lipoprotein (LDL and HDL) concentrations in blood. It is usually caused by genetic factors, secondary factors or a combination of both kinds of factors. High density lipoproteins (HDL) are also known as good cholesterol and higher levels of these help reduce the risk of cardiovascular diseases. Higher levels of low density lipoproteins (LDL) or bad cholesterol a...

  • Clinical Information Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020

    Clinical Information Systems (CIS) is a computer aided system that manages, stores and rechecks all medical information in hospitals such as health history of patients, prescriptions, doctor's notes and any other special comment whereas all information is electronically kept together. By capturing clinical data CIS makes the decision making process and clinical care delivery more efficient and effective and also helps to replace the paper work. A...

  • Urinary Tract Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Cancer associated with urinary tract is referred as urinary tract cancer. Cancer growth of cell arising from epithelial lining of urinary bladder results in urinary tract cancer. Elderly population is at a higher risk of urinary tract cancer. Although majority cases of urinary tract cancer are diagnosed at early stage, risk of re-occurrence of early diagnosed cancer is higher. Therefore, urinary tract cancer patients are recommended to undergo fo...